Sana Biotechnology (NASDAQ:SANA) Trading Up 13.9% – Still a Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose 13.9% during mid-day trading on Wednesday . The stock traded as high as $3.19 and last traded at $3.33. Approximately 1,462,380 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 21,905,322 shares. The stock had previously closed at $2.92.

Analyst Upgrades and Downgrades

A number of research analysts have commented on SANA shares. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Trading Up 17.6 %

The stock’s 50-day moving average price is $2.43 and its 200-day moving average price is $3.95. The company has a market capitalization of $766.93 million, a P/E ratio of -2.46 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SANA. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sana Biotechnology by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after buying an additional 5,338 shares during the period. Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology by 51.0% in the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock valued at $32,000 after acquiring an additional 6,694 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Sana Biotechnology by 2.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock valued at $1,056,000 after acquiring an additional 6,823 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology during the third quarter worth approximately $29,000. Finally, Stifel Financial Corp bought a new stake in Sana Biotechnology during the third quarter worth approximately $43,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.